Renal pathology: Understanding kidney damage in depth

Renal pathology is an important field of medicine that helps physicians understand the nature and extent of kidney damage by analyzing tissue samples obtained through biopsy. This technique not only provides detailed information about the microscopic structure of the kidneys but also serves as a foundation for accurately diagnosing kidney diseases, guiding treatment strategies, and predicting disease outcomes.

1. What is a kidney biopsy, and why is it necessary?

1.1. Definition of kidney biopsy

A kidney biopsy is a medical procedure in which a small sample of kidney tissue is removed for examination under a microscope [1, 7]. It is an important diagnostic tool used to evaluate kidney diseases, providing essential information about both localized kidney lesions and systemic conditions that affect kidney function [1].

1.2. The role and purpose of kidney biopsy

Kidney biopsy plays a crucial role in diagnosing, classifying, and predicting the prognosis of kidney diseases [3, 7]. It helps identify the cause of acute or chronic kidney failure of unknown origin, particularly when non-invasive tests are insufficient to establish a clear diagnosis [1, 2, 4]. Its main purposes include:

Accurate diagnosis: Helps distinguish between different types of kidney disease, including glomerulonephritis, tubulointerstitial diseases, and renal vascular diseases [1, 7].
Treatment guidance: Provides detailed information about the extent of tissue damage and disease activity, supporting the development of appropriate, individualized treatment plans [1, 4].
Prognosis: Assesses the degree of fibrosis and chronic damage, helping predict disease progression and treatment outcomes [3, 7].
Monitoring and research: Supports the monitoring of disease progression and treatment response and contributes to medical research on kidney diseases [7].

1.3. Types of kidney biopsy

There are two main types of kidney biopsy:

Targeted biopsies: Evaluate masses to look for signs of malignancy [1].
Non-targeted biopsies: Obtain samples from the renal cortex to diagnose systemic diseases affecting kidney function, such as transplant rejection, drug-related complications, diabetes, or other chronic conditions [1].

Kidney biopsies can also be classified according to the sampling method:

Percutaneous biopsy: The most common and minimally invasive method, usually performed under imaging guidance using ultrasound or computed tomography (CT) [1, 4].
Transvenous biopsy: Performed when percutaneous biopsy is contraindicated, such as in cases of severe coagulation disorders [1, 7].
Laparoscopic and open surgical biopsy: Less commonly used, generally reserved for complex cases or situations in which other methods are not feasible [1].

2. The kidney biopsy procedure

2.1. Preparation before biopsy

To ensure safety and effectiveness, patients require thorough preparation before undergoing a kidney biopsy:

Medical assessment: The physician reviews the patient's medical history and current medications and orders blood tests to assess coagulation, complete blood count, and kidney function [1].
Medication discontinuation: Patients may need to stop anticoagulants or antiplatelet medications, such as aspirin and warfarin, for a specified period before the procedure to reduce the risk of bleeding [7].
Blood pressure control: Blood pressure should be well controlled before the biopsy to minimize bleeding complications [7].
Patient education: Patients are informed about the procedure, its benefits, potential risks, and post-biopsy care [7].

2.2. Biopsy methods

Image-guided percutaneous biopsy: This is the standard method. Ultrasound or CT is used to locate the kidney and guide the biopsy needle to the appropriate site [1, 7]. Patients usually lie on their stomach or side, and local anesthesia is administered.
Transjugular renal biopsy (TJRB): This method is used when patients have a high risk of bleeding or cannot maintain the position required for percutaneous biopsy. The biopsy needle is introduced through the jugular vein, advanced into the inferior vena cava, and then into the renal vein to obtain a tissue sample [1].
Laparoscopic or open biopsy: These are alternatives when percutaneous or transvenous biopsy is not feasible or is contraindicated [1].

2.3. Sampling location and the required number of samples

For non-targeted biopsies, renal cortical tissue is generally preferred because it contains most of the glomeruli, proximal and distal convoluted tubules, and renal arterioles — structures commonly affected by kidney diseases [1]. At least 5–10 intact glomeruli are generally required for diagnosis [7]. For a comprehensive assessment, 2–3 tissue cores are usually needed for different techniques, including light microscopy, immunofluorescence, and electron microscopy [7].

3. Renal pathology: Techniques for tissue analysis

After collection, the kidney biopsy specimen is sent to the pathology laboratory for processing and analysis using several techniques, providing a comprehensive assessment of kidney damage [7].

3.1. Light microscopy (LM)

Light microscopy is the basic method for examining kidney tissue at the cellular level. To highlight different kidney structures, tissue samples are stained with specialized reagents [7]:

Hematoxylin and eosin (H&E) staining: A basic stain used to assess overall tissue architecture, cells, and inflammatory lesions [7].
Periodic acid–Schiff (PAS) staining: Highlights glomerular and tubular basement membranes and mesangial matrix, helping identify changes such as basement membrane thickening or mesangial matrix expansion [7].
Jones stain (periodic acid–methenamine silver, PAM): Similar to PAS but particularly useful for highlighting basement membrane structures and detecting spikes or a “double-contour” appearance in certain glomerular diseases [7].
Masson's trichrome staining: Differentiates collagen (blue) from other tissue components (red), making it particularly useful for assessing fibrosis and scarring in kidney tissue [7].
Congo red staining: Used to detect amyloid, an abnormal protein that accumulates in kidney tissue in amyloidosis [7].

3.2. Immunofluorescence (IF)

Immunofluorescence uses fluorescently labeled antibodies to detect immune complex deposits, including immunoglobulins and complement components, in the glomeruli, tubules, and blood vessels [7]. It is an important technique for diagnosing immune-mediated glomerular diseases, including:

Detection of immunoglobulins (IgG, IgA, IgM): Identifies deposits of these antibodies, such as those found in IgA nephropathy and membranous nephropathy [7].
Detection of complement components (C3, C1q, C4): Evaluates complement system activation in immune-mediated diseases [7].
Detection of fibrin: May indicate coagulation or vascular injury [7].
Detection of kappa and lambda light chains: Useful for diagnosing conditions associated with plasma cell disorders, such as light chain disease [7].

3.3. Electron microscopy (EM)

Electron microscopy provides very high magnification, allowing examination of cellular ultrastructure and basement membranes that cannot be visualized in sufficient detail by light microscopy [7]. EM is particularly important in the following situations:

Detection of small immune complex deposits: Helps determine the precise location of deposits, including subepithelial, intramembranous, and subendothelial deposits [7].
Assessment of the glomerular basement membrane: Detects subtle abnormalities such as thickening, thinning, splitting, or rupture of the basement membrane [7].
Examination of podocytes: Assesses foot process effacement, a characteristic finding in nephrotic syndrome [7].
Diagnosis of rare diseases: Includes Fabry disease, light chain disease, and inherited kidney disorders [7].

3.4. Other techniques: Immunohistochemistry (IHC) and in situ hybridization (ISH)

Immunohistochemistry (IHC): Uses antibodies to detect specific proteins in tissue. Similar to IF, it identifies target proteins but uses an enzyme-based color reaction rather than fluorescence [7].
In situ hybridization (ISH): Detects specific DNA or RNA sequences within cells. It is useful for diagnosing viral infections, such as BK virus infection in kidney transplant rejection, and certain genetic disorders [7].

4. Common kidney lesions identified by biopsy

Renal pathology findings allow physicians to identify and classify various types of kidney lesions, which are generally grouped into glomerular, tubulointerstitial, and renal vascular lesions.

4.1. Glomerular lesions

The glomeruli are the blood-filtering units of the kidneys. Diseases affecting these structures commonly cause proteinuria, hematuria, and impaired kidney function.

Cellular changes:
- Endothelial, mesangial, and epithelial cell proliferation: An increase in the number of these cells often indicates inflammation or autoimmune injury [7]. For example, mesangial cell proliferation is commonly seen in IgA nephropathy.
- Crescent formation: The accumulation of inflammatory cells and extracellular material in Bowman's space, commonly associated with rapidly progressive forms of glomerulonephritis [7].
Changes in the glomerular basement membrane:
- Basement membrane thickening: Commonly seen in diabetic kidney disease and membranous nephropathy [7].
- Basement membrane thinning: Characteristic of thin basement membrane disease [7].
- Double-contour formation: A sign of chronic or inflammatory injury, as seen in membranoproliferative glomerulonephritis [7].
Glomerular diseases:
- Fibrillary glomerulonephritis: Characterized by deposits of non-amyloid protein fibrils [7].
- IgA nephropathy: Characterized by predominantly mesangial IgA deposits [7].
- Nephrotic syndrome: Can result from several diseases, including minimal change disease, focal segmental glomerulosclerosis (FSGS), and membranous nephropathy. These conditions can cause podocyte injury and severe proteinuria [7].

4.2. Tubulointerstitial lesions

The tubulointerstitium consists of the kidney tubules and the surrounding connective tissue. Lesions in this area commonly affect the kidneys' ability to reabsorb and secrete substances.

Acute tubular degeneration and necrosis (acute tubular necrosis, ATN): Acute injury to tubular cells caused by ischemia or toxins, often resulting in acute kidney injury [7].
Interstitial nephritis: Inflammation of the renal interstitium, commonly caused by drug reactions or autoimmune diseases, resulting in inflammatory cell infiltration [7].
Tubulointerstitial fibrosis and tubular atrophy: Signs of chronic kidney damage in which the interstitium becomes fibrotic and the tubules atrophy, leading to permanent loss of kidney function [7].

4.3. Renal vascular lesions

Vascular lesions can affect blood flow to the kidneys and contribute to kidney disease.

Fibrinoid and hyaline changes: Deposition of proteinaceous material in blood vessel walls, commonly seen in severe hypertension or microvascular diseases [7].
Renal arteriosclerosis: Hardening of the renal arterioles, causing ischemia and chronic kidney damage [7].
Thrombosis: Obstruction of renal blood vessels by blood clots, which may lead to renal infarction [7].

5. The importance of renal pathology in diagnosis and treatment

5.1. Accurate diagnosis and disease classification

Renal pathology is considered the “gold standard” for diagnosing kidney diseases, classifying disease stages, and predicting prognosis [3, 7]. Using advanced analytical techniques, pathologists can identify the specific type of lesion, the degree of disease activity, and chronic changes [7]. This is particularly important because many kidney diseases present with similar clinical symptoms but have different underlying mechanisms and treatment requirements. For example, a biopsy can distinguish lupus nephritis from IgA nephropathy, two conditions that require substantially different treatment regimens.

5.2. Prognosis and treatment guidance

Biopsy findings not only support diagnosis but also provide valuable information for predicting disease progression [7]. The extent of fibrosis, the presence of fibrous crescents, and tubular atrophy are important factors in predicting the likelihood of kidney function recovery and the rate of progression to end-stage kidney disease [7]. Based on these findings, physicians can adjust treatment plans, such as increasing or reducing the dose of immunosuppressive medications or considering other supportive therapies. In some cases, biopsy findings may change a patient's management plan in up to 40% of cases [12].

5.3. Supporting medical research and development

Renal pathology is an indispensable tool in medical research. It helps scientists better understand the mechanisms underlying kidney diseases, identify risk factors, and develop new treatments [7]. Advanced techniques such as molecular biology, proteomics, and transcriptomics are increasingly being integrated into renal pathology to provide deeper insights into disease-causing molecular pathways, potentially paving the way for more precise therapies in the future [7].

6. When should you see a doctor?

6.1. Warning signs after a kidney biopsy

After a kidney biopsy, patients should monitor for unusual symptoms and seek immediate medical attention if any of the following occur:

Severe pain at the biopsy site or pain radiating to the abdomen or groin.
Visible hematuria (bright red or dark, cola-colored urine) or blood clots in the urine.
High fever or chills.
Shortness of breath, dizziness, or fainting, which may indicate blood loss.
Unusual swelling, redness, or discharge at the biopsy site.
Inability to urinate or a marked decrease in urine output.

6.2. Signs of progressive or abnormal kidney disease

Patients with a history of kidney disease or those undergoing ongoing monitoring should consult a doctor if they experience any of the following symptoms, as these may indicate disease progression or complications:

Edema of the face, hands, legs, or ankles, particularly if it develops suddenly or is asymmetrical.
Uncontrolled high blood pressure.
Unusual fatigue or weakness.
Nausea, vomiting, or loss of appetite.
Changes in urination: Increased nighttime urination, reduced urine output, or difficulty urinating.
Foamy urine, which may indicate proteinuria.
Unexplained back or flank pain.

7. Frequently asked questions (FAQ)

Is a kidney biopsy painful? A kidney biopsy is usually performed under local anesthesia, so patients should not feel pain during tissue collection. Some may experience pressure or mild discomfort. After the procedure, mild pain or soreness may occur at the biopsy site but can usually be managed with standard pain relievers [7].
How long does it take to receive kidney biopsy results? The time required to obtain kidney biopsy results varies depending on the laboratory and the complexity of the tests needed. Results are generally available within a few days to one week, although specialized tests, such as electron microscopy, may take longer [7]. The physician will inform you when the results are available.
Is a kidney biopsy dangerous? A kidney biopsy is a relatively safe procedure when performed by experienced specialists under imaging guidance [7]. However, like any invasive procedure, it carries certain risks, primarily bleeding, such as a perirenal hematoma or hematuria, and, less commonly, infection [7]. The rate of serious complications is very low [4, 7].
What should I do after a kidney biopsy? After the procedure, you will need to rest in bed for several hours, usually 6–24 hours depending on the biopsy method and your individual condition, to allow monitoring and reduce the risk of bleeding [7]. You should also avoid strenuous activities and heavy lifting and follow your physician's instructions regarding medication use and monitoring for warning signs at home [7].
Can a kidney biopsy miss a disease? In a small number of cases, a kidney biopsy may not yield enough tissue or the sample may not represent the full extent of the lesions, resulting in an inconclusive diagnosis or a missed disease [7]. This is particularly possible with focal lesions. If the findings are unclear or inconsistent with the clinical presentation, the physician may consider repeating the biopsy or using other diagnostic methods [7].

8. References

[1] Young, M., & Leslie, S. W. (2025). Renal Biopsy. StatPearls Publishing.
[2] Agarwal, S. K., Sethi, S., & Dinda, A. K. (2013). Basics of kidney biopsy: A nephrologist's perspective. Indian J Nephrol, 23(4), 243–252.
[3] Schnuelle, P. (2023). Renal Biopsy for Diagnosis in Kidney Disease: Indication, Technique, and Safety. J Clin Med, 12(19), 6424.
[4] Bandari, J., Fuller, T. W., Turner, R. M. II, & D'Agostino, L. A. (2016). Renal biopsy for medical renal disease: indications and contraindications. Can J Urol, 23(1), 8121–8126.
[5] Fuiano, G., Mazza, G., Comi, N., Caglioti, A., De Nicola, L., Iodice, C., ... & Andreucci, V. E. (2000). Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis, 35(3), 448–457.
[6] Hull, K. L., Adenwalla, S. F., Topham, P., & Graham-Brown, M. P. (2022). Indications and considerations for kidney biopsy: an overview of clinical considerations for the non-specialist. Clin Med (Lond), 22(1), 34–40.
[7] Schnuelle, P. (2023). Renal Biopsy for Diagnosis in Kidney Disease: Indication, Technique, and Safety. PMC.
[8] Whittier, W. L., & Korbet, S. M. (2004). Renal biopsy: update. Curr Opin Nephrol Hypertens, 13(6), 661–665.

The information above is for reference purposes only and is not intended as medical advice. Please contact your doctor for detailed medical consultation.